Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation

Abstract

Multiparameter immunophenotypic analysis of neoplastic cells has proven to be of great help for the investigation of minimal residual disease in acute leukemias; however, its utility has not been systematically explored in B cell chronic lymphoproliferative disorders. The aim of the present study was to investigate the incidence of phenotypic aberrations in a series of 467 consecutive leukemic B cell chronic lymphoproliferative disorders through the comparison of the phenotypic characteristics of tumor vs normal peripheral blood (n = 10) and bone marrow (n = 10) B cells, in order to explore the applicability of this strategy for minimal residual disease monitoring. An additional goal of our study was to evaluate the sensitivity of multiparameter flow cytometry for the detection of minimal residual disease in leukemic B cell chronic lymphoproliferative disorders through dilutional experiments (n = 19). From the patients analyzed 382 corresponded to B cell chronic lymphocytic leukemia/small lymphocytic lymphoma (353 typical and 29 atypical); five to prolymphocytic leukemia; 13 to hairy cell leukemias; 12 to lymphoplasmacytic lymphomas; 14 to splenic marginal zone lymphomas; 22 were follicular lymphomas; and 19 mantle cell lymphomas. The following triple stainings were systematically applied to both normal and leukemic samples: FMC7/CD5/CD19, CD22/CD23/CD19, CD103/CD25/CD19, CD10/CD11c/CD19 and sIg/sIgλ/CD19. Overall, 98% of the leukemic B cell chronic lymphoproliferative disorders cases displayed aberrant phenotypes at diagnosis with no significant differences being found between cases analyzed in peripheral blood vs bone marrow samples. The most common types of aberrant criteria detected included asynchronous antigen expression (92%) and antigen over-expression (54%); abnormally light scatter characteristics were found in 17% of the cases. Most of the cases studied (90%) displayed four or more phenotypic aberrations. Once patients were divided according to the different diagnostic subgroups, the overall incidence of aberrant phenotypes ranged from 79 to 80% among atypical B cell chronic lymphocytic leukemia/small lymphocytic lymphoma and prolymphocytic leukemia to 97% of follicular lymphoma and 100% of typical B cell chronic lymphocytic leukemia/small lymphocytic lymphoma, hairy cell leukemia, lymphoplasmacytic lymphomas, splenic marginal zone lymphomas and mantle cell lymphomas. Based on the aberrant phenotypes detected unique four-color stainings could be built for the specific identification of aberrant phenotypes. These include CD22/CD23/CD19/CD5 and sIgκ/sIgλ/CD19/CD5 for lymphocytic leukemia/small lymphocytic lymphoma and prolymphocytic leukemia, CD103/CD25 or CD22/CD19/CD11c for hairy cell leukemia, FMC7/CD22/CD19/CD103 and sIgκ/sIgλ/CD22/CD19 for splenic marginal zone lymphomas, CD22/CD23/CD19/CD10 for follicular lymphomas and CD10/CD22/CD19/CD5 for mantle cell lymphomas. Serial dilutional experiments showed that the sensitivity level of immunophenotyping ranges between 10−4 and 10−5. In summary, the present study shows that immunophenotypic analysis allows the identification of aberrant phenotypes in 98% of leukemic B cell chronic lymphoproliferative disorders and these phenotypes can be used for minimal residual disease monitoring with a sensitivity limit of 10−4–10−5.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. San Miguel JF, Vidriales MB, López-Berges C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C, Ramos F, Calmuntia MJ, Pérez JJ, González M, Orfao A . Early immunophenotypical evaluation of minimal residual disease (MRD) in AML identifies different patient risk-groups and may contribute to post-induction treatment stratification Blood 2001 98: 1746–1751

    Article  CAS  PubMed  Google Scholar 

  2. Ciudad J, San Miguel JF, López-Berges MC, Vidriales B, Valverde B, Ocqueteau M, Mateos G, Caballero MD, Hernández J, Moro MJ, Mateos MV, Orfao A . Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia J Clin Oncol 1998 16: 3774–3781

    Article  CAS  PubMed  Google Scholar 

  3. Lucio P, Parreira A, Van den Beemd MW, Van Lochem EG, Van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, Van Dongen JJ, San Miguel JF . Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL Leukemia 1999 13: 419–427

    Article  CAS  PubMed  Google Scholar 

  4. Cave H, Van der Werff J, Bosch T, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia N Engl J Med 1998 339: 591–598

    Article  CAS  PubMed  Google Scholar 

  5. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui CH, Campana D . Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 1998 351: 550–554

    Article  CAS  PubMed  Google Scholar 

  6. San Miguel JF, Ciudad J, Vidriales MB, Orfao A, Lucio P, Porwith-MacDonald A, Gaipa G, Van Wering E, Van Dongen JJ . Immunophenotypical detection of minimal residual disease in acute leukemia Crit Rev Oncol Hematol 1999 32: 175–185

    Article  CAS  PubMed  Google Scholar 

  7. Macedo A, Orfao A, Vidriales MB, López-Berges C, Valverde B, González M, Caballero MD, Ramos F, Martínez M, Fernández-Calvo J . Characterization of aberrant phenotypes in acute myeloblastic leukemia Ann Hematol 1995 70: 189–194

    Article  CAS  PubMed  Google Scholar 

  8. Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero MD, Blade J, Moro MJ, Hernández J, San Miguel JF . High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma Br J Haematol 1999 107: 121–131

    Article  CAS  PubMed  Google Scholar 

  9. San Miguel JF, Martinez A, Macedo A, Vidriales MB, López-Berges C, González M, Caballero D, García-Marcos MA, Ramos F, Fernández-Calvo J, Calmuntia MJ, Díaz-Mediavilla J, Orfao A . Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients Blood 1997 90: 2465–2470

    CAS  PubMed  Google Scholar 

  10. Orfao A, Ciudad J, Lopez-Berges MC, López A, Vidriales B, Caballero MD, Valverde B, González M, San Miguel JF . Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry Leuk Lymphoma 1994 13 (Suppl. 1): 87–90

    Article  Google Scholar 

  11. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 2000 343: 1750–1757

    Article  CAS  PubMed  Google Scholar 

  12. Gribben JG . Bone marrow transplantation for low-grade B cell malignancies Curr Opin Oncol 1997 9: 117–121

    Article  CAS  PubMed  Google Scholar 

  13. Montserrat E . Current therapy for CLL Hematol Cell Ther 2000 42: 31–33

    Article  CAS  PubMed  Google Scholar 

  14. Coiffier B, Thieblemont C, Felman P, Salles G, Berger F . Indolent nonfollicular lymphomas: characteristics, treatment and outcome Semin Hematol 1999 36: 198–208

    CAS  PubMed  Google Scholar 

  15. Boussiotis VA, Freedman AS, Nadler LM . Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia Semin Hematol 1999 36: 209–216

    CAS  PubMed  Google Scholar 

  16. Tallman MS, Peterson LC, Hakimian D, Gillis S, Polliack A . Treatment of hairy-cell leukemia: current views Semin Hematol 1999 36: 155–163

    CAS  PubMed  Google Scholar 

  17. Michallet M, Thiebaut A, Dreger P, Remes K, Milpied N, Santini G, Hamon M, Bjorkstrand B, Kimby E, Belhabri A, Tanguy ML, Apperley JF . Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP) Br J Haematol 2000 108: 595–601

    Article  CAS  PubMed  Google Scholar 

  18. Wendtner CM, Schmitt B, Wilhelm M, Dreger P, Montserrat E, Emmerich B, Hallek M . Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk-adapted therapy Ann Oncol 1999 10: 505–509

    Article  CAS  PubMed  Google Scholar 

  19. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC . Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxicoformycin and prediction of early relapse Clin Cancer Res 1999 5: 1665–1670

    CAS  PubMed  Google Scholar 

  20. Weiss MA, Glenn M, Maslak P, Rahman Z, Noy A, Zelenetz A, Seheinberg DA, Golde DW . Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia 2000 14: 1577–1582

    Article  CAS  PubMed  Google Scholar 

  21. Cheson BD . New prospects in the treatment of indolent lymphomas with purine analogues Cancer J Sci Am 1998 4 (Suppl. 2): 27–36

    Google Scholar 

  22. Michallet M, Corront B, Hollard D, Gratwohl A, Milpied N, Dauriac C, Brunet S, Soler J, Jouet JP, Esperou Bourdeau H . Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG Bone Marrow Transplant 1991 7: 275–279

    CAS  PubMed  Google Scholar 

  23. Hainsworth JD . Monoclonal antibody therapy in lymphoid malignancies Oncologist 2000 5: 376–384

    Article  CAS  PubMed  Google Scholar 

  24. Pavletic ZS, Bierman PJ, Vose JM, Bishop MR, Wu CD, Pierson JL, Kollath JP, Weisenburger DD, Kessinger A, Armitage JO . High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma Ann Oncol 1998 9: 1023–1026

    Article  CAS  PubMed  Google Scholar 

  25. Cabezudo E, Matutes E, Ramrattan M, Morilla R, Catovsky D . Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry Leukemia 1997 11: 1909–1914

    Article  CAS  PubMed  Google Scholar 

  26. Lenormand B, Bizet M, Fruchart C, Tilly H, Daliphard S, Thouret F, Canipel C, Callat MP, Piguet H, Lefranc MP . Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value Leukemia 1994 8: 1019–1026

    CAS  PubMed  Google Scholar 

  27. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, Russell NH, Hale G, Morgan GJ, Jack AS, Hillmen P . Quantitation of minimal residual disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy Blood 2001 98: 29–35

    Article  CAS  PubMed  Google Scholar 

  28. Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J, Lister T, Bloomfield C . World Health Organization classification of neoplastic diseases of the hematomoietic and lymphoid tissues: report of the Clinical Advisory Comittee Meeting – Airlie House, Virginia, November 1997 J Clin Oncol 1999 17: 3835–3849

    Article  CAS  PubMed  Google Scholar 

  29. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wols-Peeters C, Falini B, Gatter KC, Grogan TM, Isacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA . A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392

    CAS  PubMed  Google Scholar 

  30. García-Vela JA, Delgado I, Benito L, Monteserin MC, García-Alonso L, Somolinos N, Andreu MA, Oña F . CD79b expression in B-cell chronic lymphocytic leukemia: its implication for minimal residual disease detection Leukemia 1999 13: 1501–1505

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work has been partially supported by a grant from FONDOS FEDER (FD97-0451), Ministerio de Ciencia y Technología, Madrid, Spain. ML Sanchez is supported by a grant from FONDOS FEDER (FD97-0451), Ministerio de Ciencia y Technología, Madrid, Spain.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sánchez, M., Almeida, J., Vidriales, B. et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 16, 1460–1469 (2002). https://doi.org/10.1038/sj.leu.2402584

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402584

Keywords

This article is cited by

Search

Quick links